A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2019-04-09
Target enrollment:
Participant gender:
Summary
This is a Phase IV, prospective, multi-center, open-label study to assess the effectiveness
and safety profile of epoetin beta (Recormon®) for treatment of symptomatic anemia in adult
participants associated with low/intermediate-1-risk MDS. After screening, eligible
participants will be treated with epoetin beta as recommended in the approved label and
international guidelines for the use of epoetin in MDS participants and the dosage will be
adjusted on the basis of erythroid response.